Lineage Cell Therapeutics, Inc. (LCTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Lineage Cell Therapeutics, Inc. (LCTX) Healthcare & Pipeline Overview

Lineage Cell Therapeutics, Inc. pioneers cell therapies for degenerative diseases, including OpRegen for dry age-related macular degeneration and OPC1 for spinal cord injuries. With a focus on unmet medical needs and a gross margin of 94.2%, Lineage operates in the competitive biotechnology sector, striving to advance novel treatments.

What Is the Investment Thesis for LCTX?

Lineage Cell Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cell therapies for degenerative diseases addresses significant unmet medical needs. Key value drivers include the successful advancement of OpRegen through clinical trials, potentially capturing a substantial share of the AMD market. Positive data from the ongoing Phase I/IIa trials for OPC1 in spinal cord injuries and VAC2 in lung cancer could also drive significant stock appreciation. The company's high gross margin of 94.2% indicates strong potential profitability upon commercialization. However, the company's negative profit margin of -436.5% underscores the substantial R&D expenses and the risks inherent in clinical-stage drug development. Successful navigation of regulatory hurdles and securing additional funding will be critical for Lineage's long-term success.

Based on FMP financials and quantitative analysis

LCTX Key Highlights

Market Cap of $254M reflects investor valuation of Lineage's pipeline and technology.

• Gross Margin of 94.2% indicates strong potential profitability upon commercialization of its cell therapies.
• Profit Margin of -436.5% highlights the significant R&D investment and clinical trial expenses typical of clinical-stage biotech companies.
• Beta of 1.80 suggests higher volatility compared to the overall market, reflecting the speculative nature of biotechnology stocks.
• No Dividend Yield reflects the company's focus on reinvesting earnings into research and development.

Who Are LCTX's Competitors?

LCTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are LCTX's Key Strengths?

Proprietary cell therapy technology platform.

• Diverse pipeline of product candidates.
• Experienced management team.
• High gross margin (94.2%).

What Are LCTX's Weaknesses?

Clinical-stage company with no currently approved products.

• High R&D expenses and negative profit margin (-436.5%).
• Reliance on successful clinical trial outcomes.
• Limited financial resources.

What Could Drive LCTX Stock Higher?

Announcement of Phase 2 clinical trial results for OpRegen in dry AMD (expected 2027-2028).

• Initiation of Phase 2 clinical trial for OPC1 in acute spinal cord injuries (expected 2026).
• Release of Phase 1 clinical trial data for VAC2 in non-small cell lung cancer (expected late 2026).
• Continued progress in clinical development of OpRegen, OPC1, and VAC2.
• Potential for new partnerships and collaborations.

What Are the Key Risks for LCTX?

Financial-distress signal — its Altman Z-Score of -3.44 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for OpRegen, OPC1, or VAC2.
• Regulatory delays or rejection of product candidates.
• Competition from other biotechnology companies developing similar therapies.
• High cash burn rate and need for additional funding.
• Intellectual property disputes.

What Are the Growth Opportunities for LCTX?

• OpRegen for Dry Age-Related Macular Degeneration: The market for AMD treatments is substantial, driven by an aging population. If OpRegen demonstrates efficacy in Phase 2/3 trials, it could capture a significant share of this market. The global AMD market is projected to reach $12.7 billion by 2028. Lineage's competitive advantage lies in its cell therapy approach, which aims to restore lost function rather than just slow disease progression. Timeline: Phase 2/3 trial results expected in 2027-2028.
• OPC1 for Spinal Cord Injuries: The market for spinal cord injury treatments is underserved, with limited effective therapies available. Positive results from the ongoing Phase I/IIa trial could pave the way for a breakthrough treatment. The global spinal cord injury market is projected to reach $3.2 billion by 2027. Lineage's OPC1 therapy has the potential to improve neurological function and quality of life for patients with acute spinal cord injuries. Timeline: Phase 2 trial initiation expected in 2026.
• VAC2 for Non-Small Cell Lung Cancer: Lung cancer remains a leading cause of cancer-related deaths, creating a significant need for new and effective therapies. Lineage's VAC2 immunotherapy targets antigen-presenting dendritic cells to stimulate an immune response against cancer cells. The global non-small cell lung cancer market is projected to reach $38.5 billion by 2028. Early clinical trial data will be crucial in determining the potential of VAC2. Timeline: Phase 1 trial data expected in late 2026.
• Renevia for Facial Aesthetics: While not a primary focus, Renevia provides a source of revenue and demonstrates Lineage's capabilities in cell-based products. The global facial aesthetics market is growing, driven by increasing demand for non-invasive cosmetic procedures. The global facial aesthetics market is projected to reach $15.9 billion by 2027. Lineage can leverage its expertise in cell therapy to develop and market innovative aesthetic products. Timeline: Ongoing commercialization.
• Partnerships and Collaborations: Lineage's collaboration with Orbit Biomedical, Ltd. demonstrates its commitment to strategic partnerships. Collaborations can provide access to new technologies, funding, and expertise, accelerating the development and commercialization of its cell therapies. Seeking additional partnerships with pharmaceutical companies and research institutions will be crucial for Lineage's long-term growth. Timeline: Ongoing.

What Are LCTX's Competitive Advantages?

• Proprietary cell therapy technology.
• Patent protection for its product candidates.
• Clinical trial data demonstrating efficacy and safety.
• Strategic partnerships and collaborations.
• Expertise in cell-based product development and manufacturing.

What Does LCTX Do?

Lineage Cell Therapeutics, Inc., founded in 1990 and headquartered in Carlsbad, California, is a clinical-stage biotechnology company dedicated to developing innovative cell therapies for degenerative diseases. Originally incorporated as BioTime, Inc., the company rebranded in August 2019 to reflect its focus on cell-based therapeutics. Lineage's primary focus is on addressing unmet medical needs in areas such as retinal, neurological, and oncological disorders. Their lead product candidate, OpRegen, is a retinal pigment epithelium (RPE) cell replacement therapy currently in Phase I/IIa clinical trials for the treatment of dry age-related macular degeneration (AMD), a significant cause of vision loss in the elderly. Another key program, OPC1, is an oligodendrocyte progenitor cell therapy in Phase I/IIa trials for acute spinal cord injuries. Additionally, Lineage is developing VAC2, an allogeneic cancer immunotherapy using antigen-presenting dendritic cells, in a Phase I trial for non-small cell lung cancer. The company also markets Renevia, a facial aesthetics product. Lineage collaborates with Orbit Biomedical, Ltd. to advance its therapeutic programs. With a team of 70 employees, Lineage is committed to advancing its pipeline of cell therapies and improving patient outcomes.

What Products and Services Does LCTX Offer?

• Develop cell therapies for degenerative diseases.
• Focus on retinal, neurological, and oncological disorders.
• Develop OpRegen for dry age-related macular degeneration.
• Develop OPC1 for acute spinal cord injuries.
• Develop VAC2 for non-small cell lung cancer.
• Offer Renevia, a facial aesthetics product.
• Engage in research and development of therapeutic products.

How Does LCTX Make Money?

• Develop and commercialize cell therapies.
• Generate revenue through product sales (e.g., Renevia).
• Out-license or partner for further development and commercialization of therapies.
• Secure funding through venture capital and public offerings.

What Industry Does LCTX Operate In?

Lineage Cell Therapeutics operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high R&D costs, and stringent regulatory oversight. The market for cell therapies is projected to grow significantly, driven by an aging population and increasing prevalence of degenerative diseases. Lineage's focus on retinal, neurological, and oncological disorders positions it within key growth areas. Competitors include larger pharmaceutical companies and specialized biotech firms also developing cell-based therapies. Success in this landscape requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.

Who Are LCTX's Key Customers?

• Patients with degenerative diseases (e.g., AMD, spinal cord injuries, lung cancer).
• Physicians and healthcare providers.
• Hospitals and clinics.
• Aesthetic practices (for Renevia).

Lineage Cell Therapeutics, Inc. Financial Trajectory

Lineage Cell Therapeutics, Inc. (LCTX) reported $1.1M in revenue for Q2 FY2026, a decline of 38.0% compared to the prior quarter. The company recorded net income of $1.5M, with diluted EPS of $0.01. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, LCTX averaged $-0.03 in diluted EPS.

Company Profile

Lineage Cell Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Brian Culley. LCTX has traded publicly since 1992.

How Lineage Cell Therapeutics, Inc. Is Valued

Lineage Cell Therapeutics, Inc. carries a market capitalization of $254M, placing it in the micro-cap category. Relative to its peer group, LCTX's quantitative score of 15/100 is below the peer average of 74/100.

Key Financial Metrics

Return on assets is -58.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -20.1%, the inverse of the P/E and a quick read on earnings relative to price.

Lineage Cell Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.44 places it in the distress zone, a signal of elevated financial risk.

Lineage Cell Therapeutics, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 53.1% below estimates on average.

Over the past six months, Lineage Cell Therapeutics, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 750K shares acquired (about $975K) — insiders putting money in tends to read as conviction.

LCTX Financials

LCTX Latest News

LCTX Analyst Consensus

LCTX MoonshotScore

What Investors Ask About Lineage Cell Therapeutics, Inc. (LCTX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources